Pfizer’s Litfulo approved in Europe to treat severe alopecia areata
Litfulo works by irreversibly and selectively inhibiting JAK3 and the TEC family of kinases by blocking γ-common cytokine…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
20 Sep 23
Litfulo works by irreversibly and selectively inhibiting JAK3 and the TEC family of kinases by blocking γ-common cytokine…
19 Sep 23
Cabotegravir is approved for use in combination with safer sex practices as a pre-exposure prophylaxis (PrEP) method and…
12 Sep 23
Pfizer and BioNTech’s updated Covid-19 vaccine, Comirnaty 2023-2024, and Moderna’s Spikevax were indicated for people aged 12 years…
08 Sep 23
Ervebo is a live recombinant viral vaccine that has a VSV backbone removed for the VSV envelope glycoprotein…
01 Sep 23
The FDA has approved the firm’s ANDA for Lisdexamfetamine Dimesylate Capsules 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, and…
29 Aug 23
The sNDA filing was based on the data from Cohort 1 of the late-stage THOR trial in which…
25 Aug 23
Japan’s MHLW expands Soliris’ indication to include children who are anti-acetylcholine receptor (AChR) antibody-positive, for whom high-dose intravenous…
25 Aug 23
The marketing authorisation was based on the findings of the MATISSE and RENOIR clinical trials and follows a…
24 Aug 23
FDA accepted Pfizer and Astellas’ supplemental New Drug Application (sNDA) for Xtandi, expanding its indication to include patients…
22 Aug 23
Abrysvo, a bivalent RSV prefusion F (RSVpreF) vaccine that contains two preF proteins to optimise the protection against…